In NSCLC, the abnormal activation of the c-MET signaling pathway mainly includes MET gene amplification (52), MET exon 14 skipping mutations (53), MET gene rearrangements (54, 55), and c-MET protein overexpression (56, 57). This evidence concerns the gene MET and non-small cell lung carcinoma.